JP2017513859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513859A5 JP2017513859A5 JP2016563034A JP2016563034A JP2017513859A5 JP 2017513859 A5 JP2017513859 A5 JP 2017513859A5 JP 2016563034 A JP2016563034 A JP 2016563034A JP 2016563034 A JP2016563034 A JP 2016563034A JP 2017513859 A5 JP2017513859 A5 JP 2017513859A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- conjugate
- peg moiety
- integrin
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002202 Polyethylene glycol Substances 0.000 claims description 77
- 229920001223 polyethylene glycol Polymers 0.000 claims description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 102000006495 integrins Human genes 0.000 claims description 35
- 108010044426 integrins Proteins 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000012216 imaging agent Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- -1 antibody Proteins 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 2
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007881 chronic fibrosis Effects 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002591 hydroxyproline Drugs 0.000 claims description 2
- 238000011503 in vivo imaging Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 238000012634 optical imaging Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- UNUWYDGLEJEZFU-UHFFFAOYSA-N 2-(2-iodophenyl)butanoic acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1I UNUWYDGLEJEZFU-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- BIPRZBFRCFOBDQ-KAGUSELOSA-N dnc008567 Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C BIPRZBFRCFOBDQ-KAGUSELOSA-N 0.000 claims 1
- 102220095998 rs876660440 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- OGOMLUBUDYFIOG-UHFFFAOYSA-N 4-(4-iodophenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=C(I)C=C1 OGOMLUBUDYFIOG-UHFFFAOYSA-N 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979997P | 2014-04-15 | 2014-04-15 | |
| US61/979,997 | 2014-04-15 | ||
| PCT/US2015/025700 WO2015160770A1 (en) | 2014-04-15 | 2015-04-14 | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513859A JP2017513859A (ja) | 2017-06-01 |
| JP2017513859A5 true JP2017513859A5 (enExample) | 2018-05-31 |
| JP6789823B2 JP6789823B2 (ja) | 2020-11-25 |
Family
ID=54324485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563034A Active JP6789823B2 (ja) | 2014-04-15 | 2015-04-14 | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10919932B2 (enExample) |
| EP (1) | EP3131566B1 (enExample) |
| JP (1) | JP6789823B2 (enExample) |
| CN (1) | CN106573031B (enExample) |
| AU (2) | AU2015247833B2 (enExample) |
| CA (1) | CA2945945C (enExample) |
| ES (1) | ES2930029T3 (enExample) |
| WO (1) | WO2015160770A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6789823B2 (ja) | 2014-04-15 | 2020-11-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 |
| WO2016134164A1 (en) * | 2015-02-18 | 2016-08-25 | Memorial Sloan Kettering Cancer Center | Methods of enhancing cerenkov luminescence using nanoparticles, and compositions related thereto |
| CN108699110B (zh) * | 2015-10-23 | 2023-04-28 | 特温特大学 | 整合素结合肽及其用途 |
| AU2017283537B2 (en) | 2016-06-13 | 2021-11-11 | The Regents Of The University Of California | Alpha(V)beta(6) integrin-binding peptides and methods of use thereof |
| WO2017216564A1 (en) * | 2016-06-16 | 2017-12-21 | The University Of Liverpool | Chemical composition |
| GB201613166D0 (en) * | 2016-07-29 | 2016-09-14 | Vectura Ltd | Polymer |
| KR102498068B1 (ko) * | 2016-10-07 | 2023-02-09 | 도오쿄 인스티튜드 오브 테크놀로지 | 분기형 헤테로 단분산 폴리에틸렌 글리콜, 그 제조 방법, 및 그 결합체 |
| JP7291624B2 (ja) * | 2016-11-01 | 2023-06-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ－ｖベータ－６インテグリンリガンド及びその使用 |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| UA128250C2 (uk) | 2017-11-01 | 2024-05-22 | Ерроухед Фармасьютикалс, Інк. | Ліганди інтегринів і їх застосування |
| EP3749416A1 (en) * | 2018-02-06 | 2020-12-16 | Klinikum rechts der Isar der Technischen Universität München | Compound for intraoperative molecular bioimaging, method of making the same, use thereof in intraoperative molecular bioimaging and surgical method comprising intraoperative molecular bioimaging |
| CA3112000A1 (en) | 2018-09-07 | 2020-03-12 | The Regents Of The University Of California | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof |
| WO2020093055A2 (en) | 2018-11-02 | 2020-05-07 | Indi Molecular, Inc. | Peptide libraries with non-canonical amino acids |
| US20220249678A1 (en) * | 2019-07-10 | 2022-08-11 | The University Of Hong Kong | PEGylated synthetic KL4 peptide, Compositions and Methods Thereof |
| CN110522923A (zh) * | 2019-09-19 | 2019-12-03 | 四川大学 | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 |
| EP4038187A4 (en) * | 2019-10-02 | 2023-06-07 | Sirnaomics, Inc. | OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS |
| AU2020370362A1 (en) * | 2019-10-25 | 2022-06-02 | Children's Medical Center Corporation | Computational design of alpha(v) beta (6) integrin binding proteins |
| WO2021226432A2 (en) * | 2020-05-08 | 2021-11-11 | The Regents Of The University Of California | Methods of detecting and treating lung damage in respiratory-related viral infections |
| US20230277490A1 (en) * | 2020-07-31 | 2023-09-07 | Cedars-Sinai Medical Center | Glutamine as an anticancer therapy in solid tumors |
| WO2022087156A1 (en) * | 2020-10-20 | 2022-04-28 | The Board Of Regents Of The University Of Texas System | Proinflammatory prodrugs |
| WO2022098745A1 (en) * | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| EP4319765A1 (en) | 2021-04-08 | 2024-02-14 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| WO2024263637A1 (en) | 2023-06-20 | 2024-12-26 | The Regents Of The University Of California | Combination therapy with peptide receptor radionuclide and dna repair inhibitor |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
| US5429133A (en) | 1992-12-18 | 1995-07-04 | Neoprobe Corporation | Radiation responsive laparoscopic instrument |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| AU3374795A (en) | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| JP4215512B2 (ja) | 2001-02-26 | 2009-01-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非オリゴマー化タンデム蛍光性タンパク質 |
| WO2002087497A2 (en) * | 2001-04-26 | 2002-11-07 | Board Of Regents, The University Of Texas System | Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |
| US7469107B2 (en) | 2003-07-23 | 2008-12-23 | Lexmark International, Inc. | Method for providing imaging substance for use in an imaging device via a virtual replenishment |
| JP5398982B2 (ja) | 2004-05-24 | 2014-01-29 | ミダテック リミテッド | Ｒｎａリガンドを含むナノ粒子 |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| AU2008284047A1 (en) * | 2007-08-09 | 2009-02-12 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| AU2011232862B2 (en) * | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| EP2455104B1 (en) | 2010-11-19 | 2013-07-17 | Universitätsklinikum Freiburg | Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels |
| CU23950B1 (es) * | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
| US8895055B2 (en) | 2011-12-21 | 2014-11-25 | The Regents Of The University Of California | Telodendrimer nanodiscs without apolipoprotein |
| JP6789823B2 (ja) * | 2014-04-15 | 2020-11-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 |
| AU2017283537B2 (en) * | 2016-06-13 | 2021-11-11 | The Regents Of The University Of California | Alpha(V)beta(6) integrin-binding peptides and methods of use thereof |
| CA3112000A1 (en) * | 2018-09-07 | 2020-03-12 | The Regents Of The University Of California | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof |
-
2015
- 2015-04-14 JP JP2016563034A patent/JP6789823B2/ja active Active
- 2015-04-14 ES ES15779171T patent/ES2930029T3/es active Active
- 2015-04-14 AU AU2015247833A patent/AU2015247833B2/en active Active
- 2015-04-14 CA CA2945945A patent/CA2945945C/en active Active
- 2015-04-14 WO PCT/US2015/025700 patent/WO2015160770A1/en not_active Ceased
- 2015-04-14 CN CN201580032239.XA patent/CN106573031B/zh active Active
- 2015-04-14 EP EP15779171.6A patent/EP3131566B1/en active Active
-
2016
- 2016-10-13 US US15/292,564 patent/US10919932B2/en active Active
-
2019
- 2019-09-18 AU AU2019232847A patent/AU2019232847B2/en active Active
-
2020
- 2020-12-22 US US17/131,324 patent/US11485758B2/en active Active
-
2022
- 2022-09-15 US US17/945,457 patent/US20240101601A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513859A5 (enExample) | ||
| JP2019524871A5 (enExample) | ||
| JP6789823B2 (ja) | 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法 | |
| CN109563128B (zh) | 恶性肿瘤靶向肽 | |
| Pooja et al. | Bombesin receptors as potential targets for anticancer drug delivery and imaging | |
| ES2744225T3 (es) | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos | |
| Feng et al. | SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide | |
| Duskey et al. | Nanoparticle ligand presentation for targeting solid tumors | |
| Choksi et al. | Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy | |
| Cho et al. | Viral nanoparticles decorated with novel EGFL7 ligands enable intravital imaging of tumor neovasculature | |
| Ruoslahti | Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier | |
| Rizvi et al. | Engineering peptide drug therapeutics through chemical conjugation and implication in clinics | |
| Su et al. | Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier | |
| Guo et al. | Peptides for diagnosis and treatment of ovarian cancer | |
| US12485191B2 (en) | Radiopharmaceuticals and methods of use thereof | |
| US11369569B2 (en) | Target-specific delivery of therapeutic agents | |
| Okarvi et al. | Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma | |
| CN108697756A (zh) | Her2肽试剂和方法 | |
| CN113784735A (zh) | 诊断肺癌的方法 | |
| Jin et al. | A tumor-specific tissue-penetrating peptide enhances the efficacy of chemotherapy drugs in gastric cancer | |
| JPWO2017086090A1 (ja) | 膵癌に特異的な集積性を有するペプチド及びその使用 | |
| Hendrikx et al. | Use of Cyclic Backbone NGR‐Based SPECT to Increase Efficacy of Postmyocardial Infarction Angiogenesis Imaging | |
| US20250073355A1 (en) | Cd44-binding peptide reagents and methods | |
| R Sivashankari et al. | Peptides to target tumor vasculature and lymphatics for improved anti-angiogenesis therapy | |
| Tong et al. | A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022, 14, 1036 |